Previous issue | Volume 84 | ESPE2015 | Next issue

54th Annual ESPE

Barcelona, Spain
01 Oct 2015 - 03 Oct 2015

Card image cap
Barcelona, Spain; 1-3 October 2015 Further information

Free Communications

Beta cell disorders

Islet [delta]-Cells Contribute to the Pathobiology of Atypical Congenital Hyperinsulinism
aUniversity of Manchester, Manchester, UK; bRoyal Manchester Children’s Hospital, Manchester, UK
Novel Molecular Mechanisms of Congenital Hyperinsulinism due to Autosomal Dominant Mutations in ABCC8
aUCL Institute of Child Health, London, UK; bQueen Mary, William Harvey Heart Centre, London, UK; cInstitute of Biomedical and Clinical Science, University of Exeter, Exeter, UK; dLondon Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital, London, UK
The Use of Glucagon for Management of Severe-Persistent Hypoglycaemia in Patients with Congenital Hyperinsulinism
aCook Children’s Medical Center, Fort Worth, Texas, USA; bXeris Pharmaceuticals, Inc., Austin, Texas, USA; cChildren’s Hospital, O.v.G-University, Magdeburg, Germany; dDepartment of Paediatric Endocrinology, Royal Manchester Children’s Hospital, Manchester, UK
Pharmacokinetics of a New Suspension of Glibenclamide for Use in Young Patients and Infants with Neonatal Diabetes
aService Endocrinologie, Gynécologie et Diabétologie Pédiatrique, AP-HP, Hôpital Universitaire Necker Enfants Malades, Paris, France; bFaculté de Médecine Paris Descartes, Université Sorbonne Paris Cité, Paris, France; cUMRS 1138, Faculté de Médicine Paris Descartes, Centre de Recherche des Cordeliers, Paris, France; dUnité de Recherche Clinique, AP-HP, Hôpital Universitaire Necker Enfants Malades, Centre d’Investigation Clinique, Paris, France